Prognosis of Acute Myeloid Leukemia Following Benzene Exposure

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science information has long provided a foundation for public understanding of disease risks and preventive measures. Within this broad context, discussions of environmental exposures and their potential health impacts have been a recurring theme, often framed in terms of population-level risk factors. This heritage naturally extends to occupational settings, where workers may encounter specific chemical agents at higher concentrations than the general public. One such agent is benzene, a widely used industrial solvent and a component of crude oil and gasoline. In the mass production domain, benzene exposure is a recognized concern in industries such as chemical manufacturing, petroleum refining, and rubber production. The transition from general health awareness to occupational exposure concern involves focusing on the specific conditions under which workers might be exposed to benzene over prolonged periods. This shift in perspective moves from broad educational content about environmental health to a more targeted examination of workplace safety and the potential long-term health outcomes associated with such exposures.

Benzene as a Recognized Risk Factor for Acute Myeloid Leukemia

Benzene is a well-established myelotoxin and recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is able to augment the risk for the onset of AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The link between benzene and AML is supported by epidemiological studies showing increased mortality risks. In the Swiss National Cohort, which included approximately 2.97 million persons and 13,415 lymphohaematopoietic cancer cases, increased mortality risks per unit increase in continuous benzene exposure were observed for AML (hazard ratio 1.03, 95% confidence interval 1.00-1.06) (https://pubmed.ncbi.nlm.nih.gov/38727681/). When exposure was assessed categorically, increasing trends in risks were observed with increasing benzene exposure for AML (P=0.04) (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Additionally, childhood AML has been linked to benzene exposure, with a meta-analysis reporting an odds ratio of 1.22 (95% CI 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Clinical Presentation and Diagnosis of Benzene-Induced AML

The clinical presentation and diagnosis of AML are characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and peripheral blood, leading to bone marrow failure. Common symptoms include fatigue, fever, easy bruising or bleeding, and increased risk of infections. Diagnosis is confirmed through complete blood count, peripheral blood smear, and bone marrow aspiration and biopsy, with cytogenetic and molecular testing used to classify subtypes and guide treatment. Benzene-induced AML does not have a distinct clinical phenotype, but the prognosis for affected patients is influenced by several factors, including age, cytogenetic abnormalities, molecular mutations, and response to initial therapy. The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Mechanistic Pathways and Epigenetic Effects

Mechanistic pathways linking benzene to AML involve several biological processes. Possible mechanisms of benzene initiation of hematological tumors have been identified, including a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic effects of benzene in hematologic neoplasms, such as altered gene expression, are also considered important (https://pubmed.ncbi.nlm.nih.gov/34069279/). The carcinogenic ability of benzene has been reported, and chronic exposure can be a risk element for hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Prognosis and Long-Term Outcomes

Prognosis-related considerations for patients with benzene-induced AML are similar to those for de novo AML, but the presence of prior hematologic disorders such as myelodysplastic syndromes may worsen outcomes. The incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). Early detection of hematotoxicity and genetic toxicity in peripheral blood of exposed workers could potentially identify individuals at higher risk, allowing for earlier intervention and monitoring. However, the prognosis for AML remains guarded, with five-year survival rates varying widely based on age, cytogenetic risk group, and treatment response. For benzene-exposed populations, the risk of developing AML is elevated, and mortality from the disease is increased, as shown by the hazard ratio of 1.03 per unit increase in continuous benzene exposure (https://pubmed.ncbi.nlm.nih.gov/38727681/). The latency period for benzene-induced AML is typically years to decades after initial exposure, though precise timelines depend on cumulative dose and individual susceptibility.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between benzene exposure and acute myeloid leukemia?

Benzene is a well-established myelotoxin and recognized risk factor for AML. Chronic exposure can increase the risk of developing AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epidemiological studies, such as the Swiss National Cohort, have shown increased mortality risks for AML with increasing benzene exposure (https://pubmed.ncbi.nlm.nih.gov/38727681/).

What are the early signs of benzene-induced AML?

Early signs include fatigue, fever, easy bruising or bleeding, and increased risk of infections due to bone marrow failure. Diagnosis is confirmed through blood tests and bone marrow biopsy. Early detection of hematotoxicity and genetic toxicity in peripheral blood of exposed workers may identify individuals at higher risk (https://pubmed.ncbi.nlm.nih.gov/33429013/).

How does the prognosis of benzene-induced AML compare to de novo AML?

Prognosis is similar to de novo AML but may be worsened by prior hematologic disorders like myelodysplastic syndromes. Factors such as age, cytogenetic abnormalities, and treatment response influence outcomes. The five-year survival rate varies widely, and benzene-exposed populations have increased mortality (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.